VEGFR2/CD309 antibody (Middle Region)

Catalog No. ABIN3044301

This anti-VEGFR2/CD309 antibody is a Rabbit Polyclonal antibody detecting VEGFR2/CD309 in WB, IHC and ICC. Suitable for Human. This Primary Antibody has been cited in 6+ publications.

Quick Overview for VEGFR2/CD309 antibody (Middle Region) (ABIN3044301)

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This VEGFR2/CD309 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC)

Product Details anti-VEGFR2/CD309 Antibody

Binding Specificity: AA 454-469, Middle Region

Purpose: Anti-VEGF Receptor 2/KDR Antibody Picoband®

Sequence: HHIHWYWQLE EECANE

Cross-Reactivity (Details): No cross-reactivity with other proteins

Characteristics: Anti-VEGF Receptor 2/KDR Antibody (ABIN3044301). Tested in IHC, ICC, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Purification: Immunogen affinity purified.

Immunogen: A synthetic peptide corresponding to a sequence in the middle region of human VEGF Receptor 2.

Isotype: IgG

Application Details

Application Notes: Immunocytochemistry , 0.5-1 μg/mL, Human, -
Immunohistochemistry (Frozen Section), 0.5-1 μg/mL, Human, -
Immunohistochemistry (Paraffin-embedded Section), 0.5-1 μg/mL, Human
Western blot, 0.1-0.5 μg/mL, Human
1. Matthews, W., Jordan, C. T., Gavin, M., Jenkins, N. A., Copeland, N. G., Lemischka, I. R. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Nat. Acad. Sci. 88: 9026-9030, 1991. 2. Plate, K. H., Breier, G., Millauer, B., Ullrich, A., Risau, W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 53: 5822-5827, 1993. 3. Sait, S. N. J., Dougher-Vermazen, M., Shows, T. B., Terman, B. I. The kinase insert domain receptor gene (KDR) has been relocated to chromosome 4q11-q12. Cytogenet. Cell Genet. 70: 145-146, 1995.

Comment:

Antibody can be supported by chemiluminescence kit ABIN921124 in WB, supported by ABIN921231 in IHC(P), IHC(F) and ICC.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Concentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg Sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C,-20 °C

Storage Comment: Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

References for anti-VEGFR2/CD309 antibody (ABIN3044301)

Huang, Li, Pan, Cheng, Ren, Jia, Ma, Xu: "A novel multi-target RNAi adenovirus inhibits hepatoma cell proliferation, migration, and induction of angiogenesis." in: Oncotarget, Vol. 7, Issue 36, pp. 57705-57713, (2018) (PubMed).

Liu, Yang, Zhang, Shui, Song, Yao, Dai, Sun: "Fructopyrano-(1?4)-glucopyranose inhibits the proliferation of liver cancer cells and angiogenesis in a VEGF/VEGFR dependent manner." in: International journal of clinical and experimental medicine, Vol. 7, Issue 11, pp. 3859-69, (2014) (PubMed).

Zhu, Tuerxun, Hui, Abliz: "Effects of propranolol and isoproterenol on infantile hemangioma endothelial cells in vitro." in: Experimental and therapeutic medicine, Vol. 8, Issue 2, pp. 647-651, (2014) (PubMed).

Wang, Liu, Wang, Wang: "Correlation of the expression of vascular endothelial growth factor and its receptors with microvessel density in ovarian cancer." in: Oncology letters, Vol. 6, Issue 1, pp. 175-180, (2013) (PubMed).

Wu, You, Ma, Li, Yuan, Li, Ye, Liu, Yao, Chen, Lai, Yang: "Role of transient receptor potential ion channels and evoked levels of neuropeptides in a formaldehyde-induced model of asthma in BALB/c mice." in: PLoS ONE, Vol. 8, Issue 5, pp. e62827, (2013) (PubMed).

Sun, Chen, Song, Ren, Wei, Liu, Zhang, Lv: "Effect of visfatin on the function of endothelial progenitor cells in high-fat-fed obese rats and investigation of its mechanism of action." in: International journal of molecular medicine, Vol. 30, Issue 3, pp. 622-8, (2012) (PubMed).

Target Details for VEGFR2/CD309

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Alternative Name: KDR

Background:

Synonyms: Vascular endothelial growth factor receptor 2,VEGFR-2,2.7.10.1,Fetal liver kinase 1,FLK-1,Kinase insert domain receptor,KDR,Protein-tyrosine kinase receptor flk-1,CD309,KDR,FLK1, VEGFR2,

Tissue Specificity: Detected in cornea (at protein level). Widely expressed. .

Background: KDR (Kinase Insert Domain Receptor), also known as FLK1, VEGFR or VEGFR2, is a VEGF receptor. KDR is the human gene encoding it. Sait et al. (1995) likewise corrected the assignment to chromosome 4q11-q12 to the same region occupied also by PDGFRA and KIT, thus indicating the location of a cluster of receptor tyrosine kinase genes. Vascular endothelial growth factor (VEGF) is the only mitogen that specifically acts on endothelial cells. Its expression is upregulated by hypoxia, and its cell-surface receptor, known as fetal liver kinase-1 (Flk1) in mouse, is exclusively expressed in endothelial cells (Plate et al., 1993). Flk1 is the mouse homolog of KDR (Matthews et al., 1991).

Sequence Similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.

Molecular Weight: 80 kDa

UniProt: P35968

Pathways: RTK Signaling, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling